BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 37221679)

  • 1. Stereotactic ablative radiotherapy before resection to avoid delay for early-stage lung cancer or oligometastases during the COVID-19 pandemic: Pathologic outcomes from the SABR-BRIDGE protocol.
    Kidane B; Gerard IJ; Spicer J; Kim JO; Fiset PO; Wawryko P; Cecchini MJ; Inculet R; Abdulkarim B; Fortin D; Qiabi M; Qing G; Enns S; Bashir B; Tankel J; Wakeam E; Warner A; Kopek N; Yaremko BP; Rodrigues GB; Laba JM; Qu M; Malthaner RA; Palma DA
    Cancer; 2023 Sep; 129(18):2798-2807. PubMed ID: 37221679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial.
    Ball D; Mai GT; Vinod S; Babington S; Ruben J; Kron T; Chesson B; Herschtal A; Vanevski M; Rezo A; Elder C; Skala M; Wirth A; Wheeler G; Lim A; Shaw M; Schofield P; Irving L; Solomon B;
    Lancet Oncol; 2019 Apr; 20(4):494-503. PubMed ID: 30770291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SABR-BRIDGE:
    Kidane B; Spicer J; Kim JO; Fiset PO; Abdulkarim B; Malthaner R; Palma D
    Front Oncol; 2020; 10():580189. PubMed ID: 33072612
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Measuring the Integration of Stereotactic Ablative Radiotherapy Plus Surgery for Early-Stage Non-Small Cell Lung Cancer: A Phase 2 Clinical Trial.
    Palma DA; Nguyen TK; Louie AV; Malthaner R; Fortin D; Rodrigues GB; Yaremko B; Laba J; Kwan K; Gaede S; Lee T; Ward A; Warner A; Inculet R
    JAMA Oncol; 2019 May; 5(5):681-688. PubMed ID: 30789648
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short report: interim safety results for a phase II trial measuring the integration of stereotactic ablative radiotherapy (SABR) plus surgery for early stage non-small cell lung cancer (MISSILE-NSCLC).
    Palma DA; Nguyen TK; Kwan K; Gaede S; Landis M; Malthaner R; Fortin D; Louie AV; Frechette E; Rodrigues GB; Yaremko B; Yu E; Dar AR; Lee TY; Gratton A; Warner A; Ward A; Inculet R
    Radiat Oncol; 2017 Jan; 12(1):30. PubMed ID: 28129789
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes of stereotactic ablative radiotherapy in patients with potentially operable stage I non-small cell lung cancer.
    Lagerwaard FJ; Verstegen NE; Haasbeek CJ; Slotman BJ; Paul MA; Smit EF; Senan S
    Int J Radiat Oncol Biol Phys; 2012 May; 83(1):348-53. PubMed ID: 22104360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgery.
    Chang JY; Mehran RJ; Feng L; Verma V; Liao Z; Welsh JW; Lin SH; O'Reilly MS; Jeter MD; Balter PA; McRae SE; Berry D; Heymach JV; Roth JA;
    Lancet Oncol; 2021 Oct; 22(10):1448-1457. PubMed ID: 34529930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Post-treatment survival difference between lobectomy and stereotactic ablative radiotherapy in stage I non-small cell lung cancer in England.
    Khakwani A; Harden S; Beckett P; Baldwin D; Navani N; West D; Hubbard R
    Thorax; 2020 Mar; 75(3):237-243. PubMed ID: 31879316
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-Term Outcomes of Salvage Stereotactic Ablative Radiotherapy for Isolated Lung Recurrence of Non-Small Cell Lung Cancer: A Phase II Clinical Trial.
    Sun B; Brooks ED; Komaki R; Liao Z; Jeter M; McAleer M; Balter PA; Welsh JD; O'Reilly M; Gomez D; Hahn SM; Sepesi B; Rice DC; Heymach JV; Chang JY
    J Thorac Oncol; 2017 Jun; 12(6):983-992. PubMed ID: 28259750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term Overall Survival Outcomes in Patients with Early Stage, Peripherally Located, Non-small Cell Lung Cancer Treated with Stereotactic Ablative Radiotherapy in a Non-academic Cancer Centre.
    Wood A; Aynsley E; Kumar G; Masinghe S; Anderson M; Veeratterapillay J; Huntley C; Blower A; Green J; Johnson D; Daniel J; Curtis H; Reynolds J; Turnbull M; Harland K; Swingler A; Banham E; Burke K; Bradley J; Greenhalgh A; Peedell C
    Clin Oncol (R Coll Radiol); 2021 May; 33(5):283-291. PubMed ID: 33341333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is stereotactic ablative radiotherapy equivalent to sublobar resection in high-risk surgical patients with stage I non-small-cell lung cancer?
    Mahmood S; Bilal H; Faivre-Finn C; Shah R
    Interact Cardiovasc Thorac Surg; 2013 Nov; 17(5):845-53. PubMed ID: 23900381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stereotactic ablative radiotherapy versus surgery in older patients with stage I lung cancer.
    Park S; Kim HJ; Park IK; Kim YT; Kang CH
    Eur J Cardiothorac Surg; 2021 Jul; 60(1):74-80. PubMed ID: 33668061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stereotactic Ablative Body Radiotherapy Versus Radical Radiotherapy: Comparing Real-World Outcomes in Stage I Lung Cancer.
    Phillips I; Sandhu S; Lüchtenborg M; Harden S
    Clin Oncol (R Coll Radiol); 2019 Oct; 31(10):681-687. PubMed ID: 31377081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Forecasting the impact of stereotactic ablative radiotherapy for early-stage lung cancer on the thoracic surgery workforce.
    Edwards JP; Datta I; Hunt JD; Stefan K; Ball CG; Dixon E; Grondin SC
    Eur J Cardiothorac Surg; 2016 Jun; 49(6):1599-606. PubMed ID: 26796110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Practical considerations of single-fraction stereotactic ablative radiotherapy to the lung.
    Kang TM; Hardcastle N; Singh AK; Slotman BJ; Videtic GMM; Stephans KL; Couñago F; Louie AV; Guckenberger M; Harden SV; Plumridge NM; Siva S
    Lung Cancer; 2022 Aug; 170():185-193. PubMed ID: 35843149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of Stereotactic Ablative Radiotherapy (SABR) in Non-Small Cell Lung Cancer Measuring More Than 5 cm.
    Tekatli H; van 't Hof S; Nossent EJ; Dahele M; Verbakel WFAR; Slotman BJ; Senan S
    J Thorac Oncol; 2017 Jun; 12(6):974-982. PubMed ID: 28286243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predicting pathological complete response (pCR) after stereotactic ablative radiation therapy (SABR) of lung cancer using quantitative dynamic [
    Yang DM; Palma DA; Kwan K; Louie AV; Malthaner R; Fortin D; Rodrigues GB; Yaremko BP; Laba J; Gaede S; Warner A; Inculet R; Lee TY
    Radiat Oncol; 2021 Jan; 16(1):11. PubMed ID: 33441162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is radiofrequency ablation more effective than stereotactic ablative radiotherapy in patients with early stage medically inoperable non-small cell lung cancer?
    Bilal H; Mahmood S; Rajashanker B; Shah R
    Interact Cardiovasc Thorac Surg; 2012 Aug; 15(2):258-65. PubMed ID: 22581864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Consolidative stereotactic ablative radiotherapy (SABR) to intrapulmonary lesions is associated with prolonged progression-free survival and overall survival in oligometastatic NSCLC patients: A prospective phase 2 study.
    Blake-Cerda M; Lozano-Ruíz F; Maldonado-Magos F; de la Mata-Moya D; Díaz-García D; Lara-Mejía L; Zatarain-Barrón ZL; Cuevas-Góngora MF; Barron-Barron F; Corona-Cruz JF; Cabrera-Miranda L; Arroyo-Hernández M; Gerson R; Arrieta O
    Lung Cancer; 2021 Feb; 152():119-126. PubMed ID: 33385737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 7-year follow-up after stereotactic ablative radiotherapy for patients with stage I non-small cell lung cancer: Results of a phase 2 clinical trial.
    Sun B; Brooks ED; Komaki RU; Liao Z; Jeter MD; McAleer MF; Allen PK; Balter PA; Welsh JD; O'Reilly MS; Gomez D; Hahn SM; Roth JA; Mehran RJ; Heymach JV; Chang JY
    Cancer; 2017 Aug; 123(16):3031-3039. PubMed ID: 28346656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.